Enveda raises $311M to push nature-derived AI drugs into trials

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda raised $311M Series E at a $2B valuation. It uses AI to discover drugs from plants and microbes, not lab synthesis. Two candidates are in human trials: one for severe skin conditions, another to maintain weight loss after stopping GLP-1s. The post doesn't specify trial phases or timelines.